A bivalent mRNA COVID-19 vaccine after receipt of an original monovalent COVID-19 vaccine is effective for preventing COVID-19-related thromboembolic events, according to research published in the Jan. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Leave A Comment